FF
Lv1
40 积分
2021-12-07 加入
-
德曲妥珠单抗临床管理路径及不良反应处理中国专家共识(2024版)
12天前
已完结
-
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
6个月前
已关闭
-
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
6个月前
已完结
-
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer]
6个月前
已完结
-
[Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 edition)]
8个月前
已完结
-
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
8个月前
已完结
-
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
9个月前
已完结
-
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
9个月前
已完结
-
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
9个月前
已完结
-
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
11个月前
已完结